Stratrix
Competitors · Natera

Who are Natera’s competitors?

Natera names 17 companies as competitors in its latest annual report, on 4 fronts. 2 companies name Natera back.

Skip to the field, head to head ↓Natera company profile

Competitors it names1710-K for fiscal 2025
Companies that name it2in their own annual reports
Revenue, 2025$2.3B+36% on a year
Net margin−9%Illumina 20% · Quest Diagnostics 9%
Stratrix’s Take

Natera meets a crowd in NIPT and a single primary rival in organ health

Natera's annual report for fiscal 2025 names 17 competitors, but they don't form one field. In NIPT it lists eight, from BGI to Revvity. In organ health it says, "In organ health, our primary competitor is CareDx, Inc." In oncology it lists seven, including Exact Sciences, Guardant Health and Tempus Labs. Ask who Natera's competitor is and the honest answer is: which front?

The NIPT crowd is lopsided. Quest brought in $11.0 billion, grew 12% and kept a 9% net margin. Illumina brought in $4.3 billion and kept 20%. Revvity brought in $2.9 billion and kept 8%. Natera brought in $2.3 billion, grew 36% and ran at -9%. Several of its NIPT rivals are larger and profitable. Natera is the one growing faster.

The rivalry runs both ways. Exact Sciences and Tempus AI each name Natera in their own 10-Ks. And the contest is mostly at home: revenue outside the United States was $41.8 million, 2% of the total. Natera's position is one company in three different fights, almost all of them fought in one country.

The fronts

Where Natera says it competes

NIPT competitors
BGIBillionToOneFulgent GeneticsIlluminaLaboratory Corporation of America HoldingsMyriad GeneticsQuest DiagnosticsRevvity
“Our competitors in the NIPT space include BGI; BillionToOne Inc.; Fulgent Genetics; Illumina, through its subsidiary Verinata; Laboratory Corporation of America Holdings, or Labcorp; Myriad Genetics, Inc.; Quest Diagnostics Incorporated, or Quest; and Revvity Inc.”
In its own words · 10-K for fiscal 2025
Organ health testing competitors
CareDx
“In organ health, our primary competitor is CareDx, Inc.”
In its own words · 10-K for fiscal 2025
Oncology testing competitors
BillionToOneCaris Life SciencesExact SciencesGuardant HealthPersonalisQuestTempus Labs
“In the field of oncology, we compete with various companies that offer or seek to offer competing solutions”
In its own words · 10-K for fiscal 2025
NIPT market competitors
IlluminaVerinata
“Illumina competes with us in the NIPT market through its subsidiary, Verinata.”
In its own words · 10-K for fiscal 2025
Also named
Verinata Health
Named back

Who names Natera as a competitor

“We face competition from a variety of sources, including Ambry Genetics (owned by Tempus AI); Myriad Genetics, Inc.; Natera; Color Health, Inc.; GeneDx; Illumina; Variantyx; 3billion; a few large, established general testing companies such as Laboratory Corporation of America Holdings (LabCorp) and Quest Diagnostics…”

10-K for 2025

“Our primary competitors for our currently marketed precision oncology tests include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc., Caris Life Sciences, Guardant Health, Inc., Natera, Neogenomics, ResolutionBio, which was acquired by Agilent, and others.”

10-K for 2025
Head to head

The field, from the filings

CompanyFiscal yearRevenueGrowthNet marginEmployees
Natera2025$2.3B+36%−9%6,140
Quest Diagnostics2025$11.0B+12%9%57,000
Illumina2025$4.3B−1%20%8,600,501,430
Exact Sciences2025$3.2B+18%−6%7,200
Revvity2025$2.9B+4%8%11,000
Tempus AI2025$1.3B+83%−19%3,800

Each company’s latest fiscal year as reported to the SEC, in US dollars; fiscal years end in different months. Rivals that report outside the US or in other currencies are not shown.

Customers

How concentrated Natera’s customers are

“Revenues from customers outside the United States were $41.8 million, representing 2% of total revenues for the year ended December 31, 2025.”
In its own words · 10-K for fiscal 2025
“For the year ended December 31, 2024, revenues from customers outside the United States were $39.2 million, representing approximately 2% of total revenues.”
In its own words · 10-K for fiscal 2025
“For the year ended December 31, 2023, revenues from customers outside the United States were $34.9 million, representing approximately 3% of total revenues.”
In its own words · 10-K for fiscal 2025
The moves

What the rivals have done lately

Quest DiagnosticsAcquired Lenco Diagnostic Laboratories

“On February 12, 2024, we acquired select assets of Lenco, an independent clinical diagnostic laboratory provider serving physicians in New York, in an all-cash transaction for $111 million.” filing

Quest DiagnosticsAcquired PathAI Diagnostics

“On June 10, 2024, we acquired select assets of PathAI Diagnostics, a business that provides anatomic and digital pathology laboratory services, in an all-cash transaction for $100 million.” filing

IlluminaAcquired Fluent BioSciences

“As a result of the Fluent BioSciences acquisition in Q3 2024, we recorded a developed technology asset of $ 42 million, with a useful life of 7 years, and a customer relationship asset of $ 2 million, with a useful life of 11 years.” filing

Exact SciencesAcquired Resolution Bioscience

“On September 12, 2023, we completed the acquisition of all of the outstanding capital stock of Resolution Bioscience, Inc. from Agilent Technologies, Inc.” filing

Exact SciencesAcquired OmicEra Diagnostics, GmbH

“This was partially offset by amortization of the intangible assets acquired as part of our acquisition of OmicEra Diagnostics, GmbH in May 2022 and Resolution Bioscience in September 2023.” filing

Tempus AIAcquired SEngine Precision Medicine

“SEngine Precision Medicine LLC (including its predecessor corporation SEngine Precision Medicine, Inc.), or SEngine, a company we acquired on October 3, 2023, received a letter from an attorney representing HUB Organoids IP B.V., or HUB …” filing

Tempus AIAcquired OneOme

“Our acquisition of OneOme, Inc., or OneOme, in November 2025 further enhanced our ability to provide pharmacogenetics tests, such as DPYD.” filing

Questions

Asked about Natera’s competitors

Who are Natera's competitors?

In its annual report for fiscal 2025, Natera names 17 competitors across 4 fronts: nipt competitors, organ health testing competitors, oncology testing competitors and nipt market competitors. 10-K for fiscal 2025

Which companies name Natera as a competitor?

2 companies in our coverage name it in their own annual reports: Exact Sciences and Tempus AI.

How does Natera compare with its rivals?

Natera reported $2.3B in revenue in its latest fiscal year, +36% on a year, with a −9% net margin. Illumina: $4.3B, 20% net margin; Quest Diagnostics: $11.0B, 9% net margin.

What are the alternatives to Natera?

The companies Natera itself names as competitors are listed above, front by front, each in its own report’s words. Which matters for a given buyer depends on the job, not the list.

Is your best customer building your replacement?

How much of your revenue comes from somebody who is also trying to replace you?

See the pack →

Sources: Natera’s annual report for fiscal 2025; the annual reports of the companies that name it; each company’s financial data as reported to the SEC; Stratrix Decision Records. Analysis and data, not advice.

For information and strategic analysis only, not investment advice. Stratrix does not recommend buying, selling or holding any security.

Tools to try

More from Stratrix

The Business Model Wizard

Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.

Free · about twelve minutesBuild your Model Thesis →

Weekly email

Stratonomics, every Tuesday

One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.

We'll email you a link to confirm. Unsubscribe anytime. Privacy policy.